Dipyridamole and dobutamine stress echocardiography are gaining an increasing role in non invasive diagnosis and prognostic stratification of coronary artery disease. Both tests have shown a good sensitivity and an excellent specificity, greater than that of exercise test, in the diagnosis of coronary artery disease and they seem particularly useful in the subgroups of patients such as women, hypertensives and subjects with X syndrome, in whom exercise test has a low accuracy. In patients with recent infarction both dipyridamole and dobutamine echocardiography can identify patients with multivessel disease with greater accuracy than exercise test and can detect the site and extent of myocardial ischemia (homozonal vs heterozonal ischemia). Moreover, in patients with coronary artery disease dipyridamole echocardiography has shown a high prognostic value in predicting both death and major coronary events in the follow-up. Dobutamine and, to a lesser degree, dipyridamole echocardiography may play a significant role in the identification of viable myocardium and may therefore help in the selection of patients with depressed left ventricular function amenable to revascularization. Further studies are necessary to better delineate the usefulness and limitations of the two tests and to define the specific indications and contraindications of each test.
|Translated title of the contribution||Comparison of clinical value of dipyridamole stress echocardiography and dobutamine stress echocardiography|
|Number of pages||4|
|Publication status||Published - 1993|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Radiology Nuclear Medicine and imaging